PMID- 30779846
OWN - NLM
STAT- MEDLINE
DCOM- 20200525
LR  - 20200525
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 104
IP  - 8
DP  - 2019 Aug 1
TI  - Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year 
      Population-Based Real-World Cohort Study.
PG  - 3279-3286
LID - 10.1210/jc.2018-02526 [doi]
AB  - CONTEXT: The safety of metformin usage by diabetic psoriasis patients is unclear. 
      OBJECTIVE: To investigate the real-world safety of metformin in psoriatic 
      patients with type 2 diabetes mellitus (T2DM). DESIGN: We used the National 
      Health Insurance Research Database to perform a cohort study. Based on metformin 
      and other antidiabetic agent prescriptions, we divided all psoriasis patients 
      with T2DM into the metformin group and the nonmetformin group. The outcomes 
      included all-cause mortality, severe psoriasis, hospitalization due to psoriasis, 
      and any cause for readmission. RESULTS: The metformin group (n = 5520) and the 
      nonmetformin group (n = 3062) did not significantly differ in the risk of 
      all-cause mortality [hazard ratio (HR) 1.08; 95% CI, 0.90 to 1.30], severe 
      psoriasis (HR, 0.95; 95% CI, 0.80 to 1.09), psoriasis-related admission (HR, 
      1.32; 95% CI, 0.90 to 1.93), and any-cause readmission (HR, 0.99; 95% CI, 0.90 to 
      1.11). The dose-response analysis found no significant increase in the risk of 
      severe psoriasis and psoriasis-related admission, even with more than 80 defined 
      daily doses or 1000 mg daily dose of metformin prescribed (P for linear trend > 
      0.05). CONCLUSION: Metformin can be prescribed for diabetic psoriasis patients 
      without safety concerns.
CI  - Copyright (c) 2019 Endocrine Society.
FAU - Su, Yu-Jih
AU  - Su YJ
AD  - Division of Rheumatology, Allergy, and Immunology, Department of Internal 
      Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Chen, Tien-Hsing
AU  - Chen TH
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Keelung, Taiwan.
FAU - Hsu, Chung-Yuan
AU  - Hsu CY
AD  - Division of Rheumatology, Allergy, and Immunology, Department of Internal 
      Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Chiu, Wen-Tsen
AU  - Chiu WT
AD  - Division of Rheumatology, Allergy, and Immunology, Department of Internal 
      Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Lin, Yu-Sheng
AU  - Lin YS
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chiayi, Taiwan.
FAU - Chi, Ching-Chi
AU  - Chi CC
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
AD  - Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Female
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Psoriasis/complications/*drug therapy
MH  - Retrospective Studies
MH  - Taiwan
MH  - Treatment Outcome
EDAT- 2019/02/20 06:00
MHDA- 2020/05/26 06:00
CRDT- 2019/02/20 06:00
PHST- 2018/11/23 00:00 [received]
PHST- 2019/02/14 00:00 [accepted]
PHST- 2019/02/20 06:00 [pubmed]
PHST- 2020/05/26 06:00 [medline]
PHST- 2019/02/20 06:00 [entrez]
AID - 5328895 [pii]
AID - 10.1210/jc.2018-02526 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2019 Aug 1;104(8):3279-3286. doi: 10.1210/jc.2018-02526.